Goldman Sachs and AllianceBernstein to co-host investor launch events for the 2024 Access to Medicine Index

On 19 November, the Foundation will publish the ninth edition of the Access to Medicine Index, which explores the core role of pharmaceutical companies in expanding access to medicine in low- and middle-income countries (LMICs). The London and New York investor launch events offer an opportunity for investors and company representatives to join the Foundation and have a first glance into this report and its refreshed changemaking opportunities. Attendees will have the opportunity to explore how the risks related to access to medicine can be managed by working together, and when internal access teams within pharmaceutical companies act to improve health equity.

At the events, the Foundation will share the findings and opportunities identified in the 2024 Access to Medicine Index, empowering investors with the tools they need to actively guide pharmaceutical companies and other companies involved in healthcare to demonstrate a more sustainable profile. Attendees will also have the opportunity to engage with the Foundation in a Q&A session, attend roundtable discussions, and gain insights from global health leaders as they explore material access-to-medicine issues.

During the event, attendees can also participate in meetings with pharmaceutical companies in attendance and connect with other investors who are members of the Foundation's SDG3 Collaborative focused on promoting SDG3: Good Health and Wellbeing.

About the 2024 Access to Medicine Index 

The Access to Medicine Foundation is an independent non-profit organisation that seeks to transform the healthcare ecosystem by motivating and mobilising companies to expand access to their essential healthcare products in LMICs.

The Access to Medicine Index is a research-based publication that assesses, measures and ranks 20 of the world’s largest pharma companies on their efforts to expand access to medicine in LMICs. Based on data related to 83 diseases, conditions and pathogens that disproportionately impact people living in 113 LMICs, the Index reviews pharma companies’ activities in compliance, R&D, pricing and product delivery of essential medicines. This release marks the ninth edition of the report, which has been published every two years since 2008.

How investors use the Index

The Access to Medicine Index is viewed by asset managers, asset owners and analysts as one of the most credible resources for how to guide pharmaceutical companies and other industry stakeholders toward responsible, sustainable business models and strategies.

The Foundation already works with more than 143 investor signatories representing ~USD 22 trillion AUM through its SDG3 Collaborative. Our engagement with investors – signatories and non-signatories alike – has shown the critical role they play in utilising our findings to support and encourage companies to drive concrete change. Changemaking evolves at pace when there is deep understanding of the opportunities covered in the Index by both companies and investors.

Additional information

To attend, or for more information about the 2024 launch events, please contact Twinelle Baidoo, Investor Engagement Officer at the Access to Medicine Foundation at tbaidoo@accesstomedicinefoundation.org